BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Core Viewpoint - BridgeBio Pharma (BBIO) is expected to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The consensus EPS estimate for BridgeBio Pharma is a loss of $0.74 per share, reflecting a year-over-year change of +43.5% [3] - Revenues are anticipated to reach $150.47 million, representing a significant increase of 2459% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 1.1% higher in the last 30 days, indicating a collective reassessment by analysts [4] - The Most Accurate Estimate for BridgeBio Pharma is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.69%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, BridgeBio Pharma was expected to post a loss of $0.88 per share but actually reported a loss of -$0.95, resulting in a surprise of -7.95% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Comparison - Bausch Health (BHC), another player in the Zacks Medical - Generic Drugs industry, is expected to report earnings of $1.21 per share, with a year-over-year change of +5.2% and revenues of $2.7 billion, up 5.7% from the previous year [18][19] - Bausch's consensus EPS estimate has been revised 0.6% higher, but a lower Most Accurate Estimate has resulted in an Earnings ESP of -8.84%, making it difficult to predict an earnings beat [19][20]